Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

273.41
+0.53000.19%
Post-market: 273.410.00000.00%19:30 EDT
Volume:1.01M
Turnover:279.28M
Market Cap:13.05B
PE:-56.01
High:282.91
Open:272.78
Low:270.88
Close:272.88
52wk High:303.31
52wk Low:144.26
Shares:47.74M
Float Shares:47.20M
Volume Ratio:1.08
T/O Rate:2.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8814
EPS(LYR):-2.9122
ROE:-7.52%
ROA:4.11%
PB:4.60
PE(LYR):-93.89

Loading ...

Charles River partners with Deciphex on AI-powered digital pathology slide QC

Reuters
·
May 11

Cyber Threats Loom Over Charles River Laboratories: Rising AI-Enabled Attacks, Third-Party Risks, and Potential Financial Fallout

TIPRANKS
·
May 09

Charles River Laboratories International Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
May 09

Charles River price target raised to $220 from $200 at Evercore ISI

TIPRANKS
·
May 09

Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Charles River Labs (CRL)

TIPRANKS
·
May 09

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Benzinga Earnings
·
May 08

Charles River Labs Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 08

Charles River price target raised to $220 from $210 at Barclays

TIPRANKS
·
May 08

Barclays Reaffirms Their Buy Rating on Charles River Labs (CRL)

TIPRANKS
·
May 08

U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson

Reuters
·
May 08

Charles River Laboratories International Inc : Baird Raises Target Price to $213 From $200

THOMSON REUTERS
·
May 08

Charles River Laboratories International Inc : JP Morgan Raises Target Price to $180 From $160

THOMSON REUTERS
·
May 08

Charles River Laboratories International Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Charles River Exec Says Any Decision to Expand China Structure Will Be Based on Cost, Demand, Growth Rates and Geopolitical Considerations

THOMSON REUTERS
·
May 07

Charles River Exec Says Recent Increase in Biopharma M&a Activity Has Provided Additional Source of Capital Infusion and Exit Strategy for Biotechs

THOMSON REUTERS
·
May 07

Charles River Exec Says Demand From Start-up Biotechs Remains Tepid as Earlier Stage and Seed Funding Environment Remains Constrained

THOMSON REUTERS
·
May 07

Charles River Exec Says Improved Demand in China Seen as Indication That Chinese Market Is Rebounding and Accelerating

THOMSON REUTERS
·
May 07

Charles River Exec Says Co Closely Monitoring China Market Given Accelerated Drug Innovation and in-Licensing Activity but Also Looking at Geopolitical Risks

THOMSON REUTERS
·
May 07

Charles River Exec Says Government Funding Pressures at Nih Have Modestly Impacted Client Spending

THOMSON REUTERS
·
May 07

Charles River Exec Says Revenue From Global Biopharmaceutical Client Segment Increased in the First Quarter - Conf Call

THOMSON REUTERS
·
May 07